Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NeuroScientific Biopharmaceuticals (NSB) has completed its dosing stage of the Intraocular Pressure Glaucoma model (IOP model) on pigs
  • It says it’s too early to judge the success of the study, with analysis of a large number of histological samples and neuronal markers yet to take place
  • The company is looking forward to receiving results from the experiment
  • If successful, this will be a major outcome in ophthalmology
  • NeuroScientific is up 1.82 per cent on the market today and is trading at 28¢ apiece

NeuroScientific Biopharmaceuticals (NSB) has completed its dosing stage of the Intraocular Pressure Glaucoma model (IOP model) on pigs.

Ten animals have successfully gone through the treatment procedure, although it is still too early to judge the success of the study, which requires analysis of a large number of histological samples and neuronal markers that’s yet to be complete.

However, the company is pleased to report that execution of the experimental stage by the research team at the Lions Eye Institute was at the highest level and exceeded its expectations.

“We are eagerly waiting for the data from this pivotal pre-clinical study in our ophthalmology program and expecting to report the results by the end of this
month,” the company told the market.

Success in this study would be a major outcome in ophthalmology and would represent a major commercial opportunity at the Glaucoma field.

Positive results will allow NeuroScientific to progress in testing EmtinB in human Glaucoma patients next year. The company says this will provide the first evidence of the potential efficacy of EmtinB in patients.

Glaucoma is the leading cause of irreversible blindness in the world and affects over 300,000 Australians. Currently, there is no cure for the disease.

NeuroScientific also reported that the final data from its CVM mouse model is expected this week. It says technical issues with the fluorescence scanning equipment had caused a slight delay in finalising the study.

“Other than that, the experimental work was conducted as per the original protocol with no safety and toxicology events,” the company added.

NeuroScientific is up 1.82 per cent on the market today and is trading at 28¢ apiece at 1:24 pm AEDT.

NSB by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).